McKesson Corporation (MCK) Stock Price: $750.63-29.17 (-3.74%)
At close: Jun 18, 2026, 4:00 PM ET
The closing share price for McKesson Corporation (MCK) stock was $750.63 for Thursday, June 18, 2026, down 3.74% on the day.
Longer view (total return, dividends reinvested): past 12 months +3.4% · 3-year avg +23.2%/yr · 5-year avg +33.1%/yr
MCK Price Chart
MCK is featured in
MCK Key Metrics
See All MetricsLAST CLOSE PRICE
$750.63
52-WEEK RANGE
$637.00 - $999.00
BETA
0.32
% FROM 52W HIGH
-24.86%
MARKET CAP
$87.88B
DIVIDEND YIELD
0.44%
PE RATIO
trailing TTM
19.51
PE RATIO (FWD)
next-FY estimate
14.90
P/B RATIO
N/A
DEBT / EQUITY
-3.97
REVENUE TTM
$403.43B
NET INCOME TTM
$4.76B
NET PROFIT MARGIN TTM
1.18%
TTM TOTAL RETURN
+3.40%
3Y TOTAL RETURN
+23.22%
5Y TOTAL RETURN
+33.07%
MCK Earnings Preview
Next Earnings Date
Aug 5, 2026
47 days away
EPS Estimate
9.63
Revenue Est.
$104.00B
Last Quarter Results
EPS
$11.69
vs Estimate
$11.57
Revenue
$96.30B
vs Estimate
$101.35B
MCK Analyst Ratings
Consensus Rating
Based on 15 analysts
Average Price Target
$941.40
+25.4% upside
Low
$812.00
Current
$750.63
High
$1065.00
MCK Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2028 | $13.38 | $13.65 | $14.02 | 4 |
| Q3 2028 | $14.35 | $14.64 | $15.04 | 6 |
| Q4 2028 | $14.96 | $15.27 | $15.68 | 4 |
| Q1 2029 | $16.72 | $17.06 | $17.52 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2028 | $49.99 | $50.39 | $50.87 | 9 |
| FY 2029 | $56.77 | $57.59 | $59.00 | 3 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2028 | $117.73B | $119.55B | $122.04B | 3 |
| Q3 2028 | $124.08B | $126.01B | $128.63B | 5 |
| Q4 2028 | $127.79B | $129.76B | $132.46B | 3 |
| Q1 2029 | $116.36B | $118.16B | $120.62B | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2028 | $459.70B | $463.99B | $475.86B | 12 |
| FY 2029 | $500.48B | $501.64B | $502.79B | 11 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareMCK Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MCK | $87.88B | $750.63 | -3.74% | +3.40% | +33.07% | +16.38% | — |
| 2ELV | $84.37B | $388.50 | -0.71% | +5.55% | +2.49% | +12.92% | vs MCK |
| 3HCA | $83.23B | $375.17 | -3.35% | +0.23% | +14.20% | +17.99% | vs MCK |
| 4MDT | $101.86B | $79.34 | +1.54% | -4.53% | -5.59% | +2.05% | vs MCK |
| 5CI | $73.88B | $279.27 | -2.04% | -9.24% | +5.71% | +9.08% | vs MCK |
| 6BSX | $67.35B | $44.95 | -4.20% | -55.33% | +1.04% | +7.25% | vs MCK |
MCK Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler